Phase I study of AZD2171 co-administered with fixed multiple oral doses of ZD1839 in patients with advanced cancer
Study identifier:D8480C00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I open-label study to assess the safety, tolerability and PK of ascending multiple oral doses of AZD2171 when co-administered with fixed multiple oral doses of ZD1839 (250mg or 500mg once daily) in patients with advanced cancer
Medical condition
advanced tumor
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD2171, ZD1839
Sex
All
Actual Enrollment
65
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Aug 2004
Primary Completion Date: 01 Jun 2006
Study Completion Date: 01 Jun 2006
Study design
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Nick Botwood
AstraZeneca
